Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer

Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer

Background. Treatment results for the patients with stage II–III triple negative breast cancer (TN BC) have to be improved. Not only the new treatment regimens, but new predictive and prognostic factors should to be developed.Materials and methods. We included 98 patients with stage II–III TN BC in...

Full description

Bibliographic Details
Main Authors: O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Ganshina, G. V. Vyshinskaya, M. A. Kazantseva, M. V. Sukhova, O. E. Ryabishina, E. V. Lubennikova, D. A. Filonenko, E. I. Chichikov, I. N. Polushkina, E. I. Borisova, A. N. Lud, A. A. Meshcheryakov
Format: Article
Language:Russian
Published: ABV-press 2020-11-01
Series:Opuholi Ženskoj Reproduktivnoj Sistemy
Subjects:
triple negative breast cancer
neoadjuvant chemotherapy
pcr
predictors of pcr
prognostic factors
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/732

Internet

https://ojrs.abvpress.ru/ojrs/article/view/732

Similar Items